Myriad Genetics (MYGN) Misses Q3 EPS by 13c, Updates Guidance

Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.19), $0.13 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $156.4 million versus the consensus estimate of $170.58 million.

GUIDANCE:

Myriad Genetics sees FY2022 EPS of ($0.35)-($0.30), versus the consensus of ($0.06). Myriad Genetics sees FY2022 revenue of $668-672 million, versus the consensus of $692.2 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
• ExxonMobil outlines key factors for Q2 2026 earnings outlook
• MasTec to acquire The Superior Group for about $1.65 billion